Medacta Group Management
Management criteria checks 4/4
Medacta Group's CEO is Francesco Siccardi, appointed in Nov 2018, has a tenure of 5.33 years. total yearly compensation is €1.86M, comprised of 21.3% salary and 78.7% bonuses, including company stock and options. directly owns 19.9% of the company’s shares, worth CHF483.81M. The average tenure of the management team and the board of directors is 10.7 years and 5.2 years respectively.
Key information
Francesco Siccardi
Chief executive officer
€1.9m
Total compensation
CEO salary percentage | 21.3% |
CEO tenure | 5.3yrs |
CEO ownership | 19.9% |
Management average tenure | 10.7yrs |
Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Feb 22Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around
Feb 07Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult
Dec 18Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Dec 04Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Nov 15Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
Oct 30If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
Oct 17Is Medacta Group (VTX:MOVE) Using Too Much Debt?
Sep 29Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Aug 11Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Jul 27Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital
Jul 03At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?
Apr 28Is Medacta Group (VTX:MOVE) A Risky Investment?
Apr 08Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Dec 25Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal
Dec 09Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Nov 09Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching
Sep 16The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence
Aug 20Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors
Jul 02Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?
May 28Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
May 12These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well
Mar 31Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Mar 17Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future
Feb 07Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?
Dec 10Medacta Group (VTX:MOVE) Knows How To Allocate Capital
Nov 05Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Sep 30Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?
Aug 26Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital
Jul 20Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?
May 19We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt
Apr 05What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition
Mar 02Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?
Feb 02The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More
Jan 12Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture
Dec 21Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?
Dec 03CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | €2m | €396k | €47m |
Sep 30 2023 | n/a | n/a | €49m |
Jun 30 2023 | n/a | n/a | €50m |
Mar 31 2023 | n/a | n/a | €48m |
Dec 31 2022 | €2m | €372k | €46m |
Sep 30 2022 | n/a | n/a | €47m |
Jun 30 2022 | n/a | n/a | €47m |
Mar 31 2022 | n/a | n/a | €49m |
Dec 31 2021 | €2m | €354k | €52m |
Sep 30 2021 | n/a | n/a | €54m |
Jun 30 2021 | n/a | n/a | €57m |
Mar 31 2021 | n/a | n/a | €47m |
Dec 31 2020 | €1m | €339k | €37m |
Sep 30 2020 | n/a | n/a | €24m |
Jun 30 2020 | n/a | n/a | €10m |
Mar 31 2020 | n/a | n/a | €11m |
Dec 31 2019 | €843k | €247k | €12m |
Compensation vs Market: Francesco's total compensation ($USD2.03M) is about average for companies of similar size in the Swiss market ($USD1.69M).
Compensation vs Earnings: Francesco's compensation has been consistent with company performance over the past year.
CEO
Francesco Siccardi (46 yo)
5.3yrs
Tenure
€1,861,824
Compensation
Dr. Francesco Siccardi has been Chief Executive Officer of Medacta Group SA since November 1, 2018. He is a Member of the Board of Directors of Surgical Practice Resource Group SA, Lugano since 2015 and of...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder & Non Executive Chairman | 6.2yrs | €352.21k | 10.2% € 247.9m | |
Chief Executive Officer | 5.3yrs | €1.86m | 19.9% € 483.8m | |
Chief Financial Officer | 13.2yrs | no data | no data | |
Senior Director of Global Marketing | no data | no data | no data | |
Chief People Officer | no data | no data | no data | |
Chief Supply Chain Officer | 8.2yrs | no data | 19.8% € 481.4m | |
Head of IT | no data | no data | no data | |
Chief Commercial Officer | no data | no data | no data | |
Chief Innovation Officer | no data | no data | no data | |
Secretary of the Board | no data | no data | no data |
10.7yrs
Average Tenure
50.5yo
Average Age
Experienced Management: MOVE's management team is seasoned and experienced (10.7 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder & Non Executive Chairman | 6.2yrs | €352.21k | 10.2% € 247.9m | |
Lead Independent Director | 5.2yrs | €231.19k | 0.013% € 305.1k | |
Independent Director | 3.3yrs | €128.89k | 0.16% € 4.0m | |
Independent Director | 5yrs | €152.33k | no data | |
Non-executive Director | 6.2yrs | €137.62k | 19.8% € 481.4m |
5.2yrs
Average Tenure
63yo
Average Age
Experienced Board: MOVE's board of directors are considered experienced (5.2 years average tenure).